-
Sisram Medical Reports 2024 Interim Revenues with Growth in Key Regions and New Product Launches
•
Sisram Medical Ltd (HKG: 1696), an Israel-based subsidiary of the Fosun Pharmaceutical Group, has released its unaudited interim financial report for 2024, showing revenues of USD 168.7 million, a slight decrease of 1.7% year-on-year (YOY). The company’s regional revenue breakdown indicates growth in the Asia Pacific, Europe, Middle East, and…
-
Sisram Medical’s Profhilo Accepted for Review by China’s NMPA
•
Sisram Medical Ltd (HKG: 1696), an Israel-based company within the Fosun Pharmaceutical Group (SHA: 600196), has announced that its licensed injection filler product, Prohiro, has had its market filing accepted for review by China’s National Medical Products Administration (NMPA). Profhilo, an injectable sodium hyaluronate solution, is recognized as one of…
-
Sisram Medical Ltd Expands Asia-Pacific Presence with New Direct Sales Office in Japan
•
Sisram Medical Ltd (HKG: 1696), an Israel-based company that is part of the Fosun Pharmaceutical Group, has announced that its subsidiary, Alma Lasers, has established a new direct sales channel in Japan, marking the company’s sixth direct sales office in the Asia-Pacific region. New Sales Office and Regional ExpansionThe new…
